EICHOR
● Active Not Recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Condition: Castration-Resistant Prostatic Cancer · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (318)
| Urology Centers Of Alabama | Homewood, Alabama, United States | — |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | — |
| Urological Associates of Southern Arizona, P.C. | Tucson, Arizona, United States | — |
| Arkansas Urology | Little Rock, Arkansas, United States | — |
| Kaiser Permanente | Riverside, California, United States | — |
| San Bernardino Urological Associates | San Bernardino, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Sansum Clinic Pharm | Santa Barbara, California, United States | — |
| The Urology Center of Colorado | Denver, Colorado, United States | — |
| Colorado Clinical Research | Lakewood, Colorado, United States | — |
| VA Connecticut Healthcare | West Haven, Connecticut, United States | — |
| Bay Pines VA Healthcare System | Bay Pines, Florida, United States | — |
+ 306 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.